Endonovo Therapeutics, Inc. (ENDV) financial statements (2020 and earlier)
Company profile
| Business Address |
6320 CANOGA AVENUE WOODLAND HILLS, CA 91367 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 5 | 379 | 90 | 56 | 41 | 1 | ||
| Cash and cash equivalents | 5 | 379 | 90 | 56 | 41 | 1 | ||
| Receivables | 11 | 3 | ||||||
| Other current assets | 336 | 2 | ||||||
| Other undisclosed current assets | 23 | 21 | 247 | |||||
| Total current assets: | 39 | 382 | 111 | 303 | 378 | 3 | ||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 7 | 7 | 1 | 16 | 32 | 43 | ||
| Intangible assets, net (including goodwill) | 3,368 | 3,853 | 4,500 | |||||
| Intangible assets, net (excluding goodwill) | 3,368 | 3,853 | 4,500 | |||||
| Total noncurrent assets: | 3,375 | 3,860 | 4,501 | 16 | 32 | 43 | ||
| TOTAL ASSETS: | 3,414 | 4,242 | 4,612 | 319 | 409 | 46 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 1,474 | 943 | 2,714 | 4,738 | 3,990 | 3,167 | ||
| Accounts payable | 346 | 157 | ||||||
| Accrued liabilities | 786 | |||||||
| Interest and dividends payable | 1,128 | |||||||
| Other undisclosed accounts payable and accrued liabilities | 2,714 | 4,738 | 3,990 | 3,167 | ||||
| Debt | 6,938 | 6,054 | 4 | 12 | 12 | 1,097 | ||
| Deferred compensation liability | 2,387 | 2,246 | 1,525 | |||||
| Derivative instruments and hedges, liabilities | 7,067 | 4,426 | 5,940 | 1,928 | 3,974 | |||
| Due to related parties | 195 | 270 | 20 | 6 | 245 | 291 | ||
| Other undisclosed current liabilities | 1,763 | 1,539 | 4,731 | 2,037 | 1,265 | (1,525) | ||
| Total current liabilities: | 19,825 | 15,479 | 13,409 | 8,721 | 9,486 | 4,555 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 32 | 22 | 4 | 17 | 29 | |||
| Long-term debt, excluding current maturities | 32 | 22 | 4 | 17 | 29 | |||
| Other undisclosed noncurrent liabilities | 155 | 123 | 731 | 155 | 183 | 155 | ||
| Total noncurrent liabilities: | 155 | 155 | 753 | 159 | 199 | 184 | ||
| Total liabilities: | 19,980 | 15,634 | 14,163 | 8,881 | 9,685 | 4,739 | ||
| Temporary equity, carrying amount | 1,763 | 1,539 | 598 | |||||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent, including: | (16,566) | (11,392) | (9,550) | (8,562) | (9,276) | (4,693) | ||
| Preferred stock | 0 | 0 | 0 | |||||
| Common stock | 83 | 43 | 32 | 13 | 10 | 8 | ||
| Common stock, share subscribed but unissued, subscriptions receivable | (2) | (2) | (2) | |||||
| Common stock, value, subscriptions | (2) | (2) | (2) | |||||
| Additional paid in capital | 30,622 | 24,187 | 19,604 | 9,801 | 3,774 | 1,593 | ||
| Deferred compensation equity | (1,000) | |||||||
| Accumulated deficit | (47,270) | (35,620) | (29,184) | (18,374) | (13,059) | (6,293) | ||
| Other undisclosed stockholders' equity attributable to parent | 1,000 | 0 | ||||||
| Other undisclosed stockholders' equity | (1,763) | (1,539) | (598) | |||||
| Total stockholders' equity: | (18,329) | (12,931) | (10,148) | (8,562) | (9,276) | (4,693) | ||
| TOTAL LIABILITIES AND EQUITY: | 3,414 | 4,242 | 4,612 | 319 | 409 | 46 | ||
Income statement (P&L) ($ in thousands)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 204 | 83 | 4 | 24 | |||
| Revenue, net | ✕ | ✕ | 4 | 24 | |||
| Cost of revenue | (54) | (13) | (2) | (15) | |||
| Cost of goods and services sold | (2) | (15) | |||||
| Gross profit: | 150 | 70 | 2 | 9 | |||
| Operating expenses | (4,261) | (4,230) | (4,604) | (5,411) | (2,567) | (2,200) | |
| Other operating expense, net (Other Expenses) | (3) | ||||||
| Other undisclosed operating income | 3 | ||||||
| Operating loss: | (4,111) | (4,159) | (4,604) | (5,411) | (2,565) | (2,191) | |
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (6,157) | (2,277) | (6,206) | 95 | (4,201) | 1,411 | |
| Interest and debt expense | 27 | 317 | 2,485 | (488) | (128) | (1,411) | |
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | (27) | (317) | (2,485) | 488 | 128 | 1,232 | |
| Net loss available to common stockholders, diluted: | (10,268) | (6,436) | (10,810) | (5,316) | (6,766) | (959) | |
Comprehensive Income ($ in thousands)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (10,268) | (6,436) | (10,810) | (5,316) | (6,766) | (959) | |
| Comprehensive loss, net of tax, attributable to parent: | (10,268) | (6,436) | (10,810) | (5,316) | (6,766) | (959) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.